Slide 1: BioSyent Inc. Q2 / H1 2023 Results
BioSyent Inc. Q2 / H1 2023 Results AUGUST 22, 2023 PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX
Slide 4: Q2 / H1 2023 Sales Summary ($)
Q2 / H1 2023 Sales Summary ($) Q2 ‘23 Q2 ‘23 vs. H1 ‘23 H1 ‘23 vs. Sales ($) Q2 ’22 (%) Sales ($) H1 ’22 (%) Canadian Pharma ($) $7,722k +23% $14,133k +12% Canadian Pharma Record quarterly sales FeraMAX® +25% +13% in Q2 2023 with growth Tibella® +49% +44% from across product Combogesic® +12% (18%) p
Slide 5: Sales, EBITDA and NIAT - Q2 2023
Sales, EBITDA and NIAT Quarter (Q2) ended June 30, 2023 +20% Sales 8,000 +53% +23% Canadian Pharma -9% (100%) International Pharma 7,000 +35% (34%) Legacy 6,000 EBITDA / NIAT • EBITDA Margin 5,000 Q2 2023: 23% to Sales CAD (000's) 4,000 Q2 2022: 25% to Sales 3,000 • NIAT Margin Q2 2023: 19% to Sales
Slide 6: Sales, EBITDA and NIAT - H1 2023
Sales, EBITDA and NIAT First Half (H1) ended June 30, 2023 +36% Sales +6% -7% +12% Canadian Pharma 14,000 (100%) International Pharma +35% (39%) Legacy 12,000 EBITDA / NIAT 10,000 • +20% increase in selling & marketing expenses H1 2023 vs. H1 2022 • 2023 new product launches CAD (000's) 8,000 (FeraM
Slide 7: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 52 Consecutive Profitable Quarters Q2 2023 $1,483,190 $0.12 to Q2 2023 Q1 2023 $1,175,246 $0.10 $0.43 Q4 2022 $1,199,516 $0.09 Q3 2022 $1,453,042 $0.12 Q2 2022 $1,217,883 $0.10 Q1 2022 $1,587,904 $0.13 $0.50 Q4 2021 $1,877,804 $0.15 Q3 2021 $
Slide 8: 13 Years of Profitable Growth (and Counting!)
13 Years of Profitable Growth (and Counting!) 35,000 Annual Revenue Annual NIAT 30,000 25,000 CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 *2023* f/d shares: 14,336,194 12,194,773 8 | www.biosyent.com | TSXV: RX
Slide 9: Q2 2023 Highlights
Q2 2023 Highlights ▪ FeraMAX® named #1 Recommended iron supplement in Canada by pharmacists and physicians ▪ New Gelclair® oncology supportive care product approved by Health Canada ▪ 3rd consecutive quarterly dividend of $0.04/share paid ▪ Cathejell® Agreement extended to 2034 ▪ 173,900 shares repu
Slide 10: Most recommended iron supplement in Canada
▪ Most recommended iron supplement in Canada - pharmacists and physicians - 8 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 11: Product Innovation: A New Platform for FeraMAX
A New Platform for FeraMAX® Product Innovation ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (“PDIC”) ▪ Foundation for future product development ▪ Life Cycle Strategy – expanding leadership of FeraMAX® brand in Canada: “Iron health f
Slide 12: NEW in 2023 - FeraMAX Pd Maintenance 45
NEW in 2023 - FeraMAX® Pd Maintenance 45 ▪ Developed by BioSyent ▪ 3rd product incorporating PDIC ▪ Designed to: ▪ prevent iron deficiency ▪ maintain healthy iron levels ▪ Unique formulation: ▪ chewable ▪ pleasant taste ▪ 45 mg elemental iron ▪ supportive vitamins for iron health ▪ Launched in Canad
Slide 13: NEW in 2023 - Inofolic
NEW in 2023 - Inofolic® ▪ In-licensed by BioSyent in October 2020 ▪ New treatment option for women with Polycystic Ovary Syndrome (PCOS), an endocrine disorder which can cause: ▪ Insulin resistance ▪ Infertility ▪ Menstrual dysfunction ▪ Skin manifestations ▪ Hirsutism ▪ Alopecia ▪ Unique soft-gel c
Slide 14: NEW in 2023 - Gelclair
NEW in 2023 - Gelclair® ▪ In-licensed by BioSyent in December 2022 ▪ Oncology supportive care product for relief of oral mucositis ▪ Frequently experienced by cancer patients undergoing radiation or chemotherapy ▪ Protective concentrated gel which adheres to the mucosa of the mouth, providing: ▪ Fas
Slide 15: Growth Drivers
Growth Drivers Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis FeraMAX® Pd Platform – Life Cycle Strategy In development HRT agent for menopause therapy 1st pain relief formulation combining acetaminophen + ibuprofen in Canada Acquisition and in-licensing – ongoing
Slide 16: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) 30,000 25% • Zero Debt 21% • TTM Jun 30/23 Cash from 28,000 27,899 27,922 20% Operations of $5.4M 26,000 16% • TTM Jun 30/23 NCIB share 16% 15% buybacks: $3.4M 24,000 24,024 CAD (000's) RoE % 10% • TTM Jun 30/23 Dividends of 22,000 $1.5M 5% 20,000 • Jun 30/23
Slide 17: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $27.9M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders: • $0.04/share Dividend – Q4’22/Q1’23/Q2’23/Q3’23 = $ 2.0
Slide 18: Stock Information
Stock Information As at August 21, 2023 Exchange & Trading Symbol 0% TSXV: RX Aug 21, 2023 Closing Stock Price (CAD) $7.60 52 Week Hi/Low: $8.30 / $6.24 Issued Common Shares: 12,032,461 Treasury – RSU Shares in Trust (210,900) Outstanding Common Shares: 11,821,561 Options Outstanding 164,295 RSUs Ou
Slide 19: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 19 | www.biosyent.com | TSXV: RX